LillyDirect: Selling Around the MiddlemenNarrow moat
Eli Lilly (LLY) — moat facet
A manufacturer deliberately routing around the channel that has taken a share of its economics for thirty years.
LillyDirect is a direct-to-patient platform through which Lilly sells selected medicines, dispensed by third-party pharmacies and delivered to the patient's home, alongside tools for finding independent prescribers1. The company states that sales through it represented a growing portion of the business in 2025 and that it continues to launch new partnerships to expand access.
Read commercially, this is an attempt to change who Lilly's customer is. In the traditional channel a benefit manager negotiates a rebate, a wholesaler takes a margin, and a pharmacy dispenses; Lilly's realised price is what survives that sequence. Selling direct for cash removes the rebate entirely. It is why Lilly could price its oral product aggressively for self-pay while protecting its economics — a list price of $149 a month collects more than a much higher list price rebated down.
The risks are real and mostly relational. Benefit managers and pharmacy chains are counterparties Lilly needs for its other twenty products, and a manufacturer that visibly routes around them invites retaliation on formulary placement elsewhere in the portfolio.
Watch disclosed direct-channel revenue as a share of the total. If it becomes material without the rest of Lilly's portfolio suffering formulary punishment, the company will have solved a problem the industry has complained about for thirty years.
LillyDirect grew to a larger portion of the business in 2025 and is the mechanism behind aggressive self-pay pricing on the oral product. A dollar collected directly is worth more than a dollar collected through a rebated formulary. Widening, with the honest qualification that the channel is small and that the intermediaries being bypassed also control access for the rest of Lilly's portfolio.
Direct cash-pay sales carry lower prices. A U.S. price decline steepening past -10% would mean the direct channel is pulling the whole price down.
Source: Lilly Form 10-Q, quarter ended 30 June 2026 ↗- ReportedLillyDirect is a direct-to-patient platform whose sales represented a growing portion of the business in 2025.Eli Lilly Form 10-K, FY2025 — in 2025, 2024 and 2023 three US wholesale distributors, McKesson Corporation, Cencora, Inc. and Cardinal Health, Inc., each accounted for a significant percentage of consolidated revenue, and no other customer accounted for more than 10 percent in any of these years; wholesale distributors account for a substantial portion of trade receivables with collateral generally not required; health plans, managed care organizations, pharmacy benefit managers, wholesalers and pharmacies have consolidated into fewer, larger entities, enhancing their market power, and maintain formularies specifying coverage and reimbursement, controlling costs by negotiating discounts or rebates in exchange for formulary inclusion and placement, with unfavorable placement leading to reduced usage through prior authorizations, exclusions or higher consumer out-of-pocket cost; LillyDirect is a direct-to-patient digital platform through which sales represented a growing portion of the business in 2025 — FY2025 (ended December 31, 2025) · publ. February 12, 2026 · source ↗